This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (34)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

III. The Effect of Cortisone Administration on the Incidence of Casein-Induced Amyloidosis in the Rabbit

ALAN S. COHEN, M.D.; EVAN CALKINS, M.D.; P. FRANKLIN MULLINAX, M.D.

Arch Intern Med. 1962;110(5):569-573.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Amyloidosis continues to maintain its reputation as a disease of unknown etiology and, in nearly all instances, progressive course. In an effort to gain more understanding of the nature of this disease, investigators have attempted to define the influence on its course of a variety of external variables. This list includes nitrogen mustards and x-ray therapy (which are said to accentuate the disease) and splenectomy, which has been reported to lessen its severity.^1-6

One of the variables whose influence has practical as well as theoretical importance is the administration of adrenal cortical steroids. Questions concerning possible influence of steroid therapy on the course of amyloidosis are often raised by clinicians, especially with regard to patients with rheumatoid arthritis and nephrosis, 2 conditions which are frequently associated with amyloidosis, in which corticoid therapy may be considered.

Unfortunately, the reported effects of adrenal cortical therapy in human and experimental amyloidosis have . . . [Full Text PDF of this Article]

Author Affiliations
BOSTON

Associate Professor of Medicine, Boston University School of Medicine (Dr. Cohen); Professor of Medicine, Buffalo University School of Medicine (Dr. Calkins); Research Fellow in Microbiology, Washington University, St. Louis (Dr. Mullinax).; From the Medical Services, Massachusetts General Hospital; The Department of Medicine, Harvard Medical School, and The Robert Dawson Evans Department of Clinical Research, Massachusetts Memorial Hospitals, and Department of Medicine, Boston University School of Medicine.

Footnotes
This is publication No. 318 of the Robert W. Lovett Memorial for the Study of Crippling Disease. Grants in support of these investigations have been received from the Eli Lilly Company and from the United States Public Health Service: Grants No. A-1064 (C-3), A-3785, and A-4599 (S-1).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?